Core Viewpoint - 康臣药业 announced the cancellation of 100,000 shares that were repurchased on February 12, 2026 [1] Company Summary - 康臣药业 is taking steps to manage its share capital by canceling repurchased shares, which may indicate a strategy to enhance shareholder value [1]

Group 1 - The company, Kangchen Pharmaceutical (01681.HK), announced a share buyback on January 6, 2026, and subsequently canceled 100,000 shares on February 12, 2026 [1]

公司名稱： 康臣葯業集團有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2026年2月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | ...

Group 1 - FMR LLC increased its stake in Kangchen Pharmaceutical (01681.HK) by acquiring 349,000 shares at an average price of HKD 17.4026 per share, totaling approximately HKD 6.0735 million [1] - Following this acquisition, FMR LLC's total shareholding rose to 59,035,375 shares, increasing its ownership percentage from 6.97% to 7.02% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康臣葯業集團有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | 本月底法定/註冊股本 ...

Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

Core Viewpoint - 康臣药业 announced a share buyback plan with a total funding limit of up to 200 million HKD, followed by an additional plan to increase the funding limit by up to 100 million HKD, bringing the total to a maximum of 300 million HKD, aimed at optimizing capital structure and enhancing shareholder value [1] Group 1 - The board of directors is confident in the company's business development and future prospects, believing that the current stock price does not fully reflect its intrinsic value and long-term growth potential [1] - The share buyback plan is aligned with the company's long-term development strategy and is subject to market conditions and financing arrangements [1] - The implementation of the share buyback plan is expected to improve the management of the company's capital structure and increase net asset value per share and/or earnings per share, benefiting both the company and its shareholders [1]

Group 1 - The core point of the article is that Kangchen Pharmaceutical (01681.HK) has announced a share buyback plan totaling up to HKD 300 million, which will be executed in two phases [1] Group 2 - The first phase of the buyback plan, approved by the board, will utilize a maximum of HKD 200 million and is set to commence on June 13, 2025 [1] - The second phase, approved on January 29, 2026, will add an additional HKD 100 million to the buyback plan, bringing the total to a maximum of HKD 300 million [1] - The duration of the buyback plan will last until the conclusion of the next annual general meeting or until the shareholders withdraw or amend the buyback authorization [1]

Core Viewpoint - 康臣药业 has announced a share buyback plan totaling up to HKD 300 million, reflecting confidence in its business development and long-term growth potential [1] Group 1: Share Buyback Plan - The board of 康臣药业 has resolved to execute a share buyback plan on June 13, 2025, with a total fund not exceeding HKD 200 million for repurchasing shares in the open market [1] - An additional share buyback plan was approved on January 29, 2026, allowing for an extra fund of up to HKD 100 million, bringing the total potential fund for share buybacks to HKD 300 million [1] - The duration of the share buyback plan will last from the announcement date until the conclusion of the next annual general meeting or until the shareholders withdraw or amend the buyback authorization [1] Group 2: Business Confidence and Strategic Rationale - The board expresses strong confidence in the company's business development and future prospects, believing that the current share price does not fully reflect its intrinsic value and long-term growth potential [1] - The implementation of the share buyback plan is seen as aligning with the company's long-term development strategy, optimizing capital structure management, and potentially increasing net asset value per share and/or earnings per share, benefiting both the company and its shareholders [1]

（於開曼群島註冊成立的有限公司） （股份代號：1681） 自願性公告 根據購回授權進行 股份回購計劃 本公告乃由康臣葯業集團有限公司（「本公司」，連同其附屬公司統稱為「本集團」） 自願刊發，旨在告知本公司股東（「股東」）及潛在投資者有關本集團最新業務發展 情況。 根據股東於2025年5月22日舉行的股東週年大會所授予的一般授權，本公司董事 （「董事」）局（「董事局」）獲授權回購最多85,126,334股本公司股份（「股份」），佔於 2025年5月22日已發行股份總數的10%（「購回授權」）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 股份回購計劃將根據購回授權進行並須符合本公司組織章程大綱及組織章程細 則、上市規則、《公司收購、合併及股份回購守則》（「收購守則」）以及所有其他適 用法律法規。本公司其後將於董事局認為合適時註銷或以庫存方式持有根據股份 回購計劃回購的股份。 董事無意行使購回授權至公眾持有的股份數目低於聯交所所規定的最低百分比， 或 ...